EHR adoption may not bring costs, quality benefits

John Gregory | | Health Exec | EMR/EHR

Reporting requirements and the extra time spent learning and using new software may be limiting the payoff from using electronic health records, according to the New York Times.

Several healthcare professionals weighed in on how increased use of EHRs hasn’t always benefitted patients or providers. In one example, Peter Sutherland, MD, a family medicine physician at Morristown, Tenn.-based Healthstar Physicians, said since adopting a cloud-based system for billing and EHR in 2012, both his personal income and the group’s revenue have fallen by 8 percent.

“I’m working harder and getting a little less,” he said.

For more on Sutherland’s struggles with EHR, and what experts have to say about the disconnect between adoption and productivity, click on the link below:

Why the Economic Payoff From Technology Is So Elusive

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup